Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Date:5/21/2008

Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of products, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
5. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
(Date:8/20/2014)... 20, 2014 Northstar Global Business Services, ... months of hard work from many talented specialists, ... formulation and package design.  The new formulation for ... into the product due to overwhelming evidence of ... Snorenz Nighttime will also include these vitamins, as ...
(Date:8/20/2014)... 20, 2014 The National Association of ... results achieved by the real-time, pseudoephedrine (PSE) blocking ... Precursor Log Exchange (NPLEx), automatically blocks unlawful pseudoephedrine ... meth offenders and make arrests. Data released by ... blocked the sale of more than ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
(Date:8/21/2014)... 2014 Entries are now open for ... comprehensive national awards program totally dedicated to recognizing excellence ... executive leadership. The entry deadline is Oct. 17. , ... Insights™, the first and only national magazine entirely devoted ... , “We launched the HREI Insights Awards program last ...
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... the Medical Cannabis Network that a company located in ... to be the only marijuana patient verification ... like to welcome this new entity to our growing ... due to our belief that these claims are inaccurate. ...
(Date:8/21/2014)... Steven Reinberg HealthDay Reporter ... experimental drug shows promise in treating respiratory syncytial virus (RSV), ... "We are finally making major progress in being able to ... of serious viral pneumonia, second only to influenza virus," said ... the University of Tennessee College of Medicine in Memphis. ...
(Date:8/21/2014)... ATLANTAStrongly influenced by their self-interest, humans do not ... consequences, researchers in Georgia State University,s Brains and ... that humans are less concerned than previously believed ... findings are published in the journal Brain ... unfairness is affected by their self-interest, indicating the ...
(Date:8/21/2014)... 21, 2014 Competing in the “Best ... Greg” will screen on Monday, August 25th at 7 ... Film Festival. This festival is named in top festival ... Symphony, Sony Software, Avid, and Write Brothers. , The ... & LFX, located at 410 South Myrtle Avenue (showtimes: ...
Breaking Medicine News(10 mins):Health News:Entries Open for 2014 HREI Insights Awards™ 2Health News:Entries Open for 2014 HREI Insights Awards™ 3Health News:Entries Open for 2014 HREI Insights Awards™ 4Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Influenced by self-interest, humans less concerned about inequity to others 2Health News:Influenced by self-interest, humans less concerned about inequity to others 3Health News:“Heavy Metal Greg,” a Music Talk Show by Gregory Graham, Will Screen at Action on Film International Film Festival on 08/25/2014 2
... begin meeting the ... on Monday, BOLINGBROOK, Ill., Jan. 11 The ... will officially open its doors on Monday,January 14. After ... and facility reviews from the Illinois,Department of Public Health ...
... to improve results, study says , , FRIDAY, Jan. ... allowing for spontaneous breathing -- the so-called "wake ... mechanical ventilators in intensive care units, a new ... from ventilators and should become common practice, the ...
... of antibodies may block human immunodeficiency virus (HIV)-1 infection ... HIV-1 vaccine. The findings, published by Cell Press in ... antibody induction appears to be a key and necessary ... recent failure of vaccines that stimulated only the T ...
... 11 Welcome to Consumer,Reports Health News ... ConsumerReports.org cover issues pertaining to the efficacy ... natural medicines),mental health, diet and nutrition, food ... products, rates the effectiveness and affordability of,prescription ...
... Health loss caused by type 2 diabetes will more ... most other major causes falls, according to new research ... The research, published in the January 7 edition of ... of disease and injury in Australia from 1993 to ...
... Life Brokerage Partners,announces three new carrier relationships ... With these new additions, Life Brokerage,Partners provides ... of the most,exclusive national insurance carriers and ... agency., New relationships with Midland National, ...
Cached Medicine News:Health News:Adventist Bolingbrook Hospital Opens to the Public 2Health News:Dual Treatment Helps Wean Patients From Ventilators 2Health News:Dual Treatment Helps Wean Patients From Ventilators 3Health News:Uncovering the Achilles' heel of the HIV-1 envelope 2Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:UQ research predicts type 2 diabetes explosion 2Health News:Life Brokerage Partners Adds New Insurance Carriers 2
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
... Accutrol is similar in design to the ... incorporates a temperature probe at the tip ... can accurately determine the patient's core body ... accuracy comparable to a pulmonary artery catheter ...
... Ultra Micro Shafts For Insertion Through ... For Light-Weight ... ,Curved Shafts For A More Comfortable Approach., ... ,Protective Cap Supplied For Protection Of Jaws ...
The New Easy-To-Use Disposable Diamond Knife Cleaning System Can Remove Even Baked-On Debris In Seconds. It Is Much More Effective Than Steam Or Blocks Of Styrofoam, Much Safer For Employees As Wel...
Medicine Products: